Exploiting Conformational Dynamics in Drug Discovery: Design of C-Terminal Inhibitors of Hsp90 with Improved Activities

The interaction that occurs between molecules is a dynamic process that impacts both structural and conformational properties of the ligand and the ligand binding site. Herein, we investigate the dynamic cross-talk between a protein and the ligand as a source for new opportunities in ligand design. Analysis of the formation/disappearance of protein pockets produced in response to a first-generation inhibitor assisted in the identification of functional groups that could be introduced onto scaffolds to facilitate optimal binding, which allowed for increased binding with previously uncharacterized regions. MD simulations were used to elucidate primary changes that occur in the Hsp90 C-terminal binding pocket in the presence of first-generation ligands. This data was then used to design ligands that adapt to these receptor conformations, which provides access to an energy landscape that is not visible in a static model. The newly synthesized compounds demonstrated antiproliferative activity at ∼150 nM concentration. The method identified herein may be used to design chemical probes that provide additional information on structural variations of Hsp90 C-terminal binding site.

[1]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[2]  H. Nymeyer,et al.  Simulation of the folding equilibrium of α-helical peptides: A comparison of the generalized Born approximation with explicit solvent , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[4]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[5]  R. Rappuoli,et al.  The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.

[6]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[7]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[8]  David A. Agard,et al.  Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements , 2006, Cell.

[9]  Johannes Buchner,et al.  Hsp90 is regulated by a switch point in the C‐terminal domain , 2009, EMBO reports.

[10]  B. Blagg,et al.  The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. , 2008, The Journal of organic chemistry.

[11]  R. Nussinov,et al.  The origin of allosteric functional modulation: multiple pre-existing pathways. , 2009, Structure.

[12]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[13]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[14]  J. Zorn,et al.  Turning enzymes ON with small molecules. , 2010, Nature chemical biology.

[15]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[16]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[17]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[18]  Lila M Gierasch,et al.  The changing landscape of protein allostery. , 2006, Current opinion in structural biology.

[19]  Anshuman Dixit,et al.  Elucidation of the Hsp90 C-terminal inhibitor binding site. , 2011, ACS chemical biology.

[20]  C. Chennubhotla,et al.  Coupling between global dynamics and signal transduction pathways: a mechanism of allostery for chaperonin GroEL. , 2008, Molecular bioSystems.

[21]  R. Nussinov,et al.  Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms , 2009, Molecular bioSystems.

[22]  J. Mccammon,et al.  Molecular recognition and ligand association. , 2013, Annual review of physical chemistry.

[23]  J Andrew McCammon,et al.  Studying functional dynamics in bio-molecules using accelerated molecular dynamics. , 2011, Physical chemistry chemical physics : PCCP.

[24]  J A McCammon,et al.  Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.

[25]  Heather A. Carlson,et al.  Incorporating Dynamics in E. coli Dihydrofolate Reductase Enhances Structure-Based Drug Discovery , 2007, J. Chem. Inf. Model..

[26]  F. Bushman,et al.  Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.

[27]  Elisabetta Moroni,et al.  3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. , 2013, ACS medicinal chemistry letters.

[28]  Adam Godzik,et al.  Divergent evolution of protein conformational dynamics in dihydrofolate reductase , 2013, Nature Structural &Molecular Biology.

[29]  David A Agard,et al.  Conformational dynamics of the molecular chaperone Hsp90 , 2011, Quarterly Reviews of Biophysics.

[30]  Gennady Verkhivker,et al.  Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. , 2010, Journal of chemical theory and computation.

[31]  J Andrew McCammon,et al.  Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach. , 2002, Journal of the American Chemical Society.

[32]  X. Daura,et al.  Peptide Folding: When Simulation Meets Experiment , 1999 .

[33]  J. Peyrat,et al.  Recent advances in Hsp90 inhibitors as antitumor agents. , 2008, Anti-cancer agents in medicinal chemistry.

[34]  Paul Workman,et al.  Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.

[35]  Stewart A. Adcock,et al.  Molecular dynamics: survey of methods for simulating the activity of proteins. , 2006, Chemical reviews.

[36]  J. Wells,et al.  Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.

[37]  Giorgio Colombo,et al.  Corresponding Functional Dynamics across the Hsp90 Chaperone Family: Insights from a Multiscale Analysis of MD Simulations , 2012, PLoS Comput. Biol..

[38]  Ruben Abagyan,et al.  A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE) , 2008, J. Comput. Aided Mol. Des..

[39]  Andrew E. Torda,et al.  The GROMOS biomolecular simulation program package , 1999 .

[40]  Giorgio Colombo,et al.  Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..

[41]  Friedrich Förster,et al.  Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. , 2008, Structure.

[42]  J Andrew McCammon,et al.  Molecular docking of balanol to dynamics snapshots of protein kinase A , 2005, Proteins.

[43]  Katrina W Lexa,et al.  Protein flexibility in docking and surface mapping , 2012, Quarterly Reviews of Biophysics.

[44]  Paul Workman,et al.  Overview: translating Hsp90 biology into Hsp90 drugs. , 2003, Current cancer drug targets.

[45]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[46]  Heather A. Carlson,et al.  Automated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design , 2008, J. Comput. Aided Mol. Des..

[47]  L. Neckers,et al.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.

[48]  Jason E Gestwicki,et al.  Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation , 2004, Science.

[49]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[50]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[51]  Martin Hessling,et al.  The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis , 2009, Nature Structural &Molecular Biology.

[52]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[53]  Anthony Maxwell,et al.  Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. , 2006, Journal of the American Chemical Society.

[54]  P. Sexton,et al.  Molecular Pharmacology , 1965, Nature.

[55]  Lila M. Gierasch,et al.  Sending Signals Dynamically , 2009, Science.

[56]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[57]  B. Blagg,et al.  Targeting the heat shock protein 90 dimer with dimeric inhibitors. , 2011, Journal of medicinal chemistry.

[58]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[59]  J Andrew McCammon,et al.  On the use of molecular dynamics receptor conformations for virtual screening. , 2012, Methods in molecular biology.

[60]  David A Agard,et al.  Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. , 2008, Molecular cell.

[61]  Heather A Carlson,et al.  Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.

[62]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997 .

[63]  B. Blagg,et al.  Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. , 2011, Journal of medicinal chemistry.

[64]  Heather A Carlson,et al.  Differences between high- and low-affinity complexes of enzymes and nonenzymes. , 2008, Journal of medicinal chemistry.

[65]  Johannes Buchner,et al.  hsp90: Twist and Fold , 2006, Cell.

[66]  Huiping Zhao,et al.  Cytotoxic sugar analogues of an optimized novobiocin scaffold , 2010 .

[67]  R. Immormino,et al.  Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. , 2007, Molecular cell.

[68]  Xiao Ming Yu,et al.  Hsp90 inhibitors identified from a library of novobiocin analogues. , 2005, Journal of the American Chemical Society.

[69]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.